Microcystic Adnexal Carcinoma (MAC): Mohs Indications & Treatment

Microcystic adnexal carcinoma (MAC), also known as sclerosing sweat duct carcinoma, is a rare, locally aggressive appendageal (adnexal) neoplasm first described by Goldstein, Barr, and Buxton in 1982. MAC is classified as an adnexal carcinoma with combined follicular and eccrine (sweat duct) differentiation. This dual differentiation is a defining feature that distinguishes it from other adnexal tumors. The incidence is very low, estimated at approximately 0.07 per 100,000 person-years, making it one of the rarer cutaneous malignancies encountered in clinical practice. MAC shows a strong predilection for the centrofacial region, with the nasolabial fold and upper lip being the most common sites (accounting for approximately 50-60% of cases), followed by the periorbital area, chin, and cheek. This centrofacial distribution is important for clinical suspicion and distinguishes MAC from many other adnexal tumors. The typical patient is a middle-aged White adult (median age 50-60 years), with a slight female predominance in most series. A history of prior radiation therapy to the affected area is a well-documented risk factor, with some series reporting radiation exposure in up to 19% of MAC patients. Cases have been reported arising in radiation fields years to decades after therapeutic irradiation. MAC is considered locally aggressive but has an extremely low metastatic potential. Distant metastasis is exceedingly rare, with fewer than 10 well-documented cases in the literature. Regional lymph node metastasis has been reported in isolated cases but remains an exceptional event.

MAC typically presents as a slow-growing, skin-colored to yellowish, firm, indurated plaque or nodule on the centrofacial area. The lesion is often poorly demarcated and may be subtle, lacking the dramatic clinical features that prompt urgent biopsy. Surface changes are usually minimal. The overlying skin may appear normal, slightly waxy, or have a mild yellowish hue, and ulceration is uncommon. The tumor grows insidiously over months to years, and many patients report having the lesion for 5-10 years or more before diagnosis. This protracted clinical course contributes to the frequent misdiagnosis of MAC as a benign condition such as a cyst, scar, morphea, or other benign adnexal tumor. Numbness, paresthesia, or pain in the distribution of the affected area may be the presenting symptom due to perineural invasion, particularly along branches of the trigeminal nerve. When sensory symptoms are present, they strongly suggest nerve involvement and should heighten suspicion for MAC or another neurotropic malignancy. The lesion is typically fixed to underlying tissue and may feel deeply tethered on palpation, reflecting the characteristic deep infiltration into subcutaneous fat, muscle, and even periosteum. Induration extending well beyond the visible borders of the lesion is a hallmark clinical finding that reflects the extensive subclinical extension.

MAC has a distinctive histopathologic architecture that is best appreciated on a deep biopsy or excision specimen. The hallmark feature is dual (combined) follicular and eccrine differentiation, with a characteristic zonation pattern: the superficial portion of the tumor shows predominantly follicular differentiation with small keratinous (infundibular) cysts and basaloid epithelial nests, while the deeper portion transitions to eccrine/ductal differentiation with small, tadpole-shaped ducts and narrow epithelial cords infiltrating through a dense, sclerotic (desmoplastic) stroma. This biphasic pattern has been described as a "paisley tie" or "tadpole" pattern and is one of the most recognizable features when the tumor is adequately sampled. The stroma is characteristically dense, fibrotic, and sclerotic, often appearing more prominent than the epithelial component. Individual tumor cells are cytologically bland with minimal atypia and low mitotic activity, which contributes to the frequent misdiagnosis as a benign process on superficial biopsies. The tumor infiltrates diffusely with narrow cords and strands of epithelial cells extending deep into the subcutaneous fat, skeletal muscle, and even periosteum, often far beyond the clinically apparent tumor margin. Subclinical extension of 2-3 cm or more beyond the clinical borders is characteristic and well-documented.

The differential diagnosis of MAC is critically important because MAC is frequently confused with both benign adnexal tumors and other infiltrative malignancies. Accurate diagnosis requires integration of clinical context (location, patient age, slow growth), adequate biopsy depth, and a thorough IHC panel. The five most important entities in the differential diagnosis are desmoplastic trichoepithelioma, morpheaform (sclerosing) basal cell carcinoma, syringoma, desmoplastic squamous cell carcinoma, and metastatic adenocarcinoma. The distinction from desmoplastic trichoepithelioma is the most clinically consequential, as it is the most common misdiagnosis and carries fundamentally different management implications. Desmoplastic trichoepithelioma is benign and requires only conservative management, while MAC requires aggressive surgical treatment with Mohs.

Mohs micrographic surgery is the gold standard treatment for microcystic adnexal carcinoma and represents one of the classic, textbook indications for the Mohs technique. The rationale for Mohs is compelling and multifactorial: MAC exhibits extensive, irregular subclinical extension that is routinely 2-3 cm beyond the clinical margins (and can extend even further), often tracking along nerve sheaths in an unpredictable, asymmetric pattern. Standard wide local excision (WLE) with predetermined margins has been associated with unacceptably high recurrence rates of 40-60% in the published literature, even with margins of 1-2 cm. In contrast, Mohs micrographic surgery achieves recurrence rates of less than 5%. An order-of-magnitude improvement in local control. The tissue-sparing advantage of Mohs is particularly important given the centrofacial location of most MAC tumors, where wide excision with adequate margins would produce significant functional and cosmetic morbidity. MAC is listed as an appropriate use criterion (AUC score 9. Most appropriate) for Mohs surgery by the AAD/ACMS guidelines, reflecting the consensus among dermatologic surgeons that Mohs is the clearly preferred treatment approach.

Perineural invasion (PNI) is one of the most clinically significant features of MAC and represents a major therapeutic challenge. PNI is present in approximately 70-80% of MAC cases, making it more consistently neurotropic than virtually any other cutaneous malignancy. The pattern of PNI in MAC is characteristically extensive: tumor cells track along nerve sheaths in a circumferential pattern, involving multiple nerve fascicles and progressing proximally along nerve trunks from small unnamed dermal nerves to larger named branches of the trigeminal nerve (most commonly the infraorbital nerve, mental nerve, and supraorbital nerve). In advanced cases, PNI can extend along named nerves to the skull base foramina (infraorbital foramen, mental foramen, supraorbital foramen) and even into the cranial cavity. The management of PNI in MAC requires a tiered, risk-stratified approach based on the caliber of the involved nerves and the extent of proximal tracking.

The treatment algorithm for MAC is centered on Mohs micrographic surgery as the primary and preferred treatment modality, with additional interventions guided by the extent of perineural invasion, margin status, and imaging findings. Unlike BCC and SCC, there is no established role for chemotherapy, targeted therapy, or immunotherapy in MAC. The tumor is too rare for large-scale clinical trials, and the exceedingly low metastatic rate means systemic therapy is almost never needed. The treatment approach follows a stepwise algorithm beginning with adequate diagnostic biopsy and pre-operative assessment, proceeding through Mohs surgery, and culminating in adjuvant therapy decisions based on final pathology.

The overall prognosis for MAC is favorable when treated with appropriate surgery (Mohs micrographic surgery), reflecting the tumor's locally aggressive but rarely metastatic biology. Distant metastasis from MAC is exceedingly rare, with fewer than 10 well-documented cases in the entire literature, resulting in a metastatic rate of less than 1%. Regional lymph node metastasis has been reported in isolated cases but is equally rare. Disease-specific mortality from MAC is extremely low. The primary clinical concern is local recurrence, which is driven by the extensive subclinical extension and perineural invasion. With Mohs surgery, local recurrence rates are consistently reported at less than 5%, compared to 40-60% with standard wide local excision. However, recurrences after MAC can occur very late. Cases have been reported more than 10 years after initial treatment. Necessitating extended long-term follow-up. Recurrent MAC is generally more difficult to treat than primary MAC because of scar tissue complicating histologic interpretation and the potential for deeper nerve involvement in recurrent disease.